Literature DB >> 27388248

Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy.

Takahiko Izumi1, Hideki Koizumi1, Ichiro Maruko1, Yohei Takahashi1, Shozo Sonoda2, Taiji Sakamoto2, Tomohiro Iida1.   

Abstract

BACKGROUND/AIMS: To investigate the changes in the intrachoroidal structures after half-dose verteporfin photodynamic therapy (PDT) for central serous chorioretinopathy (CSC).
METHODS: Swept-source optical coherence tomography cross-sectional images of 22 eyes of 22 patients with CSC were retrospectively analysed by a manual delineation technique and binarisation method.
RESULTS: In the 22 eyes, the mean subfoveal choroidal thickness decreased from 412.9±112.9 μm at baseline to 340.0±111.0 μm at 3 months (p<0.0001). The mean thickness of the large choroidal vessel layer decreased from 368.7±112.7 μm at baseline to 292.2±118.0 μm at 3 months (p<0.0001), but the mean choriocapillaris-medium choroidal vessel layer thickness did not change from 44.2±29.2 μm at baseline to 47.8±25.7 μm at 3 months (p=0.85). Analyses of the binarised choroidal images showed that a 3 mm subfoveal choroidal area decreased from 1.141±0.290 mm2 at baseline to 0.962±0.320 mm2 at 3 months after PDT (p=0.0001). The mean luminal areas decreased from 0.826±0.246 mm2 at baseline to 0.665±0.234 mm2 at 3 months (p=0.0001), however, the mean stromal areas did not change from 0.315±0.066 mm2 at baseline to 0.297±0.095 mm2 at 3 months (p=0.60).
CONCLUSIONS: Half-dose PDT reduces subfoveal choroidal thickness and alters the intrachoroidal structures in eyes with CSC. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Choroid; Imaging; Macula; Treatment Lasers; Treatment Medical

Mesh:

Substances:

Year:  2016        PMID: 27388248     DOI: 10.1136/bjophthalmol-2016-308921

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.

Authors:  Wookyung Park; Mirinae Kim; Rae Young Kim; Young-Hoon Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-31       Impact factor: 3.117

2.  Comparison of subfoveal choroidal structures in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yohei Takahashi; Hideki Koizumi; Taiji Hasegawa; Takahiko Izumi; Ichiro Maruko; Shozo Sonoda; Taiji Sakamoto; Tomohiro Iida
Journal:  Jpn J Ophthalmol       Date:  2018-08-01       Impact factor: 2.447

3.  Semi-automated software to measure luminal and stromal areas of choroid in optical coherence tomographic images.

Authors:  Shozo Sonoda; Taiji Sakamoto; Naoko Kakiuchi; Hideki Shiihara; Tomonori Sakoguchi; Masatoshi Tomita; Takehiro Yamashita; Eisuke Uchino
Journal:  Jpn J Ophthalmol       Date:  2017-12-21       Impact factor: 2.447

4.  Morphological differences of choroid in central serous chorioretinopathy determined by ultra-widefield optical coherence tomography.

Authors:  Takahiko Izumi; Ichiro Maruko; Taizo Kawano; Manabu Sakaihara; Tomohiro Iida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-19       Impact factor: 3.117

Review 5.  Pachychoroid disease spectrum: review article.

Authors:  Thiago José Muniz Machado Mazzeo; Henrique Monteiro Leber; Allan Gomes da Silva; Raimunda Cristina Mendonça Freire; Gabriel Castilho Sandoval Barbosa; Guilherme Garcia Criado; Gabriel Almeida Veiga Jacob; Cleide Guimarães Machado; André Marcelo Vieira Gomes
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-14       Impact factor: 3.117

6.  Evaluation of the choroidal vascularity index after subthreshold yellow laser treatment in the patients with chronic central serous chorioretinopathy.

Authors:  Sema Tamer Kaderli; Aylin Karalezli; Ahmet Kaderli; Simay Can Taskin; Sabahattin Sul
Journal:  Eye (Lond)       Date:  2022-05-13       Impact factor: 4.456

7.  Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Authors:  Xing-Wang Chen; Fang-Yuan Han; Gang Su; Le Pan; Shan-Jun Cai
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 8.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

Review 9.  Pachychoroid disease.

Authors:  Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund
Journal:  Eye (Lond)       Date:  2018-07-11       Impact factor: 3.775

10.  Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Shun Kumashiro; Seiji Takagi; Takashi Itokawa; Akiko Tajima; Tatsuhiko Kobayashi; Yuichi Hori
Journal:  BMC Ophthalmol       Date:  2021-05-31       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.